Tempus AI Inc
NASDAQ:TEM
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
24.96
77.62
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Tempus AI Inc
Net Issuance of Common Stock
Tempus AI Inc
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
Tempus AI Inc
NASDAQ:TEM
|
Net Issuance of Common Stock
$41.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Net Issuance of Common Stock
-$3B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Danaher Corp
NYSE:DHR
|
Net Issuance of Common Stock
-$5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Net Issuance of Common Stock
-$791.1m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-8%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Net Issuance of Common Stock
-$1.1B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-57%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Net Issuance of Common Stock
-$493m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-13%
|
|
Tempus AI Inc
Glance View
Tempus AI Inc. stands at the forefront of the healthcare technology revolution, focusing its expertise on the convergence of artificial intelligence and big data to transform the way doctors approach precision medicine. Founded by Eric Lefkofsky in 2015, the company’s mission is to harness the power of data, equipping physicians with crucial insights that can propel patient care forward. With its sprawling genomic database, Tempus aggregates clinical and molecular information, which is then meticulously analyzed to provide actionable insights. Physicians receive comprehensive reports, offering tailored therapeutic options and clinical trial opportunities that might otherwise remain undiscovered. Monetization for Tempus hinges on its relationships with various stakeholders in the healthcare ecosystem. It primarily earns revenue through partnerships with pharmaceutical companies, where it assists in drug discovery and development by offering detailed genomic data and analytics. Moreover, Tempus collaborates with research institutes and healthcare providers who rely on its AI-driven platform to enhance clinical decision-making and improve treatment outcomes. By bridging the gap between vast datasets and intricate patient care solutions, Tempus not only facilitates better healthcare practices but also solidifies its role as a vital link in the evolving landscape of modern medicine.
See Also
What is Tempus AI Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
41.3m
USD
Based on the financial report for Dec 31, 2023, Tempus AI Inc's Net Issuance of Common Stock amounts to 41.3m USD.
What is Tempus AI Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 1Y
-55%
Over the last year, the Net Issuance of Common Stock growth was -55%.
You don't have any saved screeners yet
